Cyclosporin-A to prevent graft-versus-host disease: A pilot study in 22 patients receiving allogeneic marrow transplants

P. J. Tutschka, W. E. Beschorner, A. D. Hess, G. W. Santos

Research output: Contribution to journalArticle

Abstract

Cyclosporin-A (CsA) was given to 22 patients who received allogeneic bone marrow transplants as therapy for aplastic anemia and hematologic malignancies. The drug was given daily for 180 days starting with the day of marrow infusion. Engraftment was not impaired and myelotoxicity was not observed. Cutaneous graft-versus-host disease (GVHD) developed in five patients and all either spontaneously resolved or promptly responded to therapy with steroids. Five patients developed systemic GVHD and all responded to therapy with steroids, but only two survived. Interstitial pneumonia was seen in six patients and was fatal in all of them. Liver function abnormalities were seen in 14 patients but could not positively correlated with CsA administration. Renal function abnormalities were seen in 17 patients, with renal failure in 9, requiring dialysis in 3 patients. Amphotericin-B therapy contributed significantly to the renal failure. Serum levels of CsA, measured by radioimmunoassay, could not be correlated with the presence of liver or renal function abnormalities. Overall survival so far has been 50.0%. Second malignancies were not observed, but one patient relapsed with leukemia at 343 days.

Original languageEnglish (US)
Pages (from-to)318-325
Number of pages8
JournalBlood
Volume61
Issue number2
StatePublished - 1983

Fingerprint

Transplants
Graft vs Host Disease
Grafts
Cyclosporine
Bone Marrow
Liver
Steroids
Dialysis
Amphotericin B
Bone
Renal Insufficiency
Kidney
Pharmaceutical Preparations
Second Primary Neoplasms
Aplastic Anemia
Interstitial Lung Diseases
Hematologic Neoplasms
Therapeutics
Radioimmunoassay
Leukemia

ASJC Scopus subject areas

  • Hematology

Cite this

Tutschka, P. J., Beschorner, W. E., Hess, A. D., & Santos, G. W. (1983). Cyclosporin-A to prevent graft-versus-host disease: A pilot study in 22 patients receiving allogeneic marrow transplants. Blood, 61(2), 318-325.

Cyclosporin-A to prevent graft-versus-host disease : A pilot study in 22 patients receiving allogeneic marrow transplants. / Tutschka, P. J.; Beschorner, W. E.; Hess, A. D.; Santos, G. W.

In: Blood, Vol. 61, No. 2, 1983, p. 318-325.

Research output: Contribution to journalArticle

Tutschka, PJ, Beschorner, WE, Hess, AD & Santos, GW 1983, 'Cyclosporin-A to prevent graft-versus-host disease: A pilot study in 22 patients receiving allogeneic marrow transplants', Blood, vol. 61, no. 2, pp. 318-325.
Tutschka, P. J. ; Beschorner, W. E. ; Hess, A. D. ; Santos, G. W. / Cyclosporin-A to prevent graft-versus-host disease : A pilot study in 22 patients receiving allogeneic marrow transplants. In: Blood. 1983 ; Vol. 61, No. 2. pp. 318-325.
@article{fa8a07d964d04de1ae5fb22c39b30478,
title = "Cyclosporin-A to prevent graft-versus-host disease: A pilot study in 22 patients receiving allogeneic marrow transplants",
abstract = "Cyclosporin-A (CsA) was given to 22 patients who received allogeneic bone marrow transplants as therapy for aplastic anemia and hematologic malignancies. The drug was given daily for 180 days starting with the day of marrow infusion. Engraftment was not impaired and myelotoxicity was not observed. Cutaneous graft-versus-host disease (GVHD) developed in five patients and all either spontaneously resolved or promptly responded to therapy with steroids. Five patients developed systemic GVHD and all responded to therapy with steroids, but only two survived. Interstitial pneumonia was seen in six patients and was fatal in all of them. Liver function abnormalities were seen in 14 patients but could not positively correlated with CsA administration. Renal function abnormalities were seen in 17 patients, with renal failure in 9, requiring dialysis in 3 patients. Amphotericin-B therapy contributed significantly to the renal failure. Serum levels of CsA, measured by radioimmunoassay, could not be correlated with the presence of liver or renal function abnormalities. Overall survival so far has been 50.0{\%}. Second malignancies were not observed, but one patient relapsed with leukemia at 343 days.",
author = "Tutschka, {P. J.} and Beschorner, {W. E.} and Hess, {A. D.} and Santos, {G. W.}",
year = "1983",
language = "English (US)",
volume = "61",
pages = "318--325",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Cyclosporin-A to prevent graft-versus-host disease

T2 - A pilot study in 22 patients receiving allogeneic marrow transplants

AU - Tutschka, P. J.

AU - Beschorner, W. E.

AU - Hess, A. D.

AU - Santos, G. W.

PY - 1983

Y1 - 1983

N2 - Cyclosporin-A (CsA) was given to 22 patients who received allogeneic bone marrow transplants as therapy for aplastic anemia and hematologic malignancies. The drug was given daily for 180 days starting with the day of marrow infusion. Engraftment was not impaired and myelotoxicity was not observed. Cutaneous graft-versus-host disease (GVHD) developed in five patients and all either spontaneously resolved or promptly responded to therapy with steroids. Five patients developed systemic GVHD and all responded to therapy with steroids, but only two survived. Interstitial pneumonia was seen in six patients and was fatal in all of them. Liver function abnormalities were seen in 14 patients but could not positively correlated with CsA administration. Renal function abnormalities were seen in 17 patients, with renal failure in 9, requiring dialysis in 3 patients. Amphotericin-B therapy contributed significantly to the renal failure. Serum levels of CsA, measured by radioimmunoassay, could not be correlated with the presence of liver or renal function abnormalities. Overall survival so far has been 50.0%. Second malignancies were not observed, but one patient relapsed with leukemia at 343 days.

AB - Cyclosporin-A (CsA) was given to 22 patients who received allogeneic bone marrow transplants as therapy for aplastic anemia and hematologic malignancies. The drug was given daily for 180 days starting with the day of marrow infusion. Engraftment was not impaired and myelotoxicity was not observed. Cutaneous graft-versus-host disease (GVHD) developed in five patients and all either spontaneously resolved or promptly responded to therapy with steroids. Five patients developed systemic GVHD and all responded to therapy with steroids, but only two survived. Interstitial pneumonia was seen in six patients and was fatal in all of them. Liver function abnormalities were seen in 14 patients but could not positively correlated with CsA administration. Renal function abnormalities were seen in 17 patients, with renal failure in 9, requiring dialysis in 3 patients. Amphotericin-B therapy contributed significantly to the renal failure. Serum levels of CsA, measured by radioimmunoassay, could not be correlated with the presence of liver or renal function abnormalities. Overall survival so far has been 50.0%. Second malignancies were not observed, but one patient relapsed with leukemia at 343 days.

UR - http://www.scopus.com/inward/record.url?scp=0020693944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020693944&partnerID=8YFLogxK

M3 - Article

C2 - 6336959

AN - SCOPUS:0020693944

VL - 61

SP - 318

EP - 325

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -